| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.60M | $128.67M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 800 | $13.85 | $11,080.00 | +0.3% | |
| Aug 6, 2024 | Patel Snehal | CEO And CFO | Buy | 2,000 | $13.81 | $27,620.00 | - | |
| Aug 5, 2024 | Patel Snehal | CEO And CFO | Buy | 5,500 | $13.18 | $72,490.00 | - | |
| Aug 2, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $15.15 | $15,150.00 | +0.4% | |
| Jul 23, 2024 | Patel Snehal | CEO And CFO | Buy | 1,500 | $15.89 | $23,835.00 | - | |
| Jul 18, 2024 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $16.00 | $16,000.00 | +0.4% | |
| Jun 13, 2024 | Patel Snehal | CEO And CFO | Buy | 174,825 | $14.30 | $2,499,997.50 | +3.3% | |
| Apr 1, 2024 | Patel Snehal | CEO And CFO | Buy | 3,000 | $19.08 | $57,240.00 | - | |
| Mar 22, 2024 | Patel Snehal | CEO And CFO | Buy | 2,500 | $19.98 | $49,950.00 | - | |
| Mar 20, 2024 | Patel Snehal | CEO And CFO | Buy | 1,500 | $17.68 | $26,520.00 | - |